Controversy Over Haffkine's Legacy: The DPT Vaccine Seed Strain Debate
Jayant Patil opposes Maharashtra's plan to sell DPT vaccine seed strain to a private firm, highlighting Haffkine Bio-Pharmaceutical's ability to produce affordable vaccines. He urges the cancellation of the sale, which threatens Haffkine's legacy, and reinforces concerns over commercial interests in a public health matter.
- Country:
- India
NCP leader Jayant Patil has raised objections against Maharashtra's plans to sell the DPT vaccine seed strain to a private entity.
Patil argues that state-run Haffkine Bio-Pharmaceutical Corporation could offer these vaccines affordably, thus preserving the legacy of bacteriologist Waldemar Haffkine.
The proposed sale to Reliance Life Sciences raises concerns over privatization of a public health asset, valued in the billions, drawing criticism from other political figures.
ALSO READ
-
CDC Report Delay Sparks COVID-19 Vaccine Effectiveness Debate
-
WHO Unveils Global Pandemic R&D Roadmaps to Accelerate Vaccine Development
-
Major Changes in US Health Sector: Medicare Boost, Vaccine Panel Revamp & Big Acquisitions
-
Bangladesh's Urgent Vaccine Drive Amid Measles Outbreak
-
Robert F. Kennedy Jr. Rewrites Vaccine Advisory Rules Amid Controversy
Google News